临床和实验医学杂志
臨床和實驗醫學雜誌
림상화실험의학잡지
Journal of Clinical and Experimental Medicine
2015年
19期
1633-1635
,共3页
子宫内膜异位症%恶变%卵巢癌%临床特征%预后
子宮內膜異位癥%噁變%卵巢癌%臨床特徵%預後
자궁내막이위증%악변%란소암%림상특정%예후
Endometriosis%Malignant%Oarian cancer%Clinical feature%Prognosis
目的：比较分析卵巢子宫内膜异位症（EMs）恶变与卵巢癌的临床特征及预后。方法选择由 EMs 恶变而来的卵巢癌病例共43例（研究组），另选择该组病例具有相同组织学亚型的卵巢癌病例共86例为对照组。比较两组的临床特征并随访。结果研究组年龄﹤40岁患者的比率显著高于对照组，术前 CA125水平正常的患者比率显著高于对照组，化疗周期≥6周期的患者比率显著高于（ P ﹤0.05）。研究组患者中 FIGO 分期 I 期者比率较高，对照组则 III 期的比率高。研究组3年生存率为83.33%（35/42）高于对照组69.41%（59/85），但差异无统计学意义（χ2=2.984，P =0.015）。将两组合并后对影响生存率的因素进行 COX 回归分析发现，FIGO 分期、是否 EMs 恶变、化疗周期是影响卵巢癌患者生存的因素。结论 EMs 恶变是影响卵巢癌患者预后的重要危险因素，EMs 恶变而来的卵巢癌相对预后略好，但仍应争取早期治疗。
目的：比較分析卵巢子宮內膜異位癥（EMs）噁變與卵巢癌的臨床特徵及預後。方法選擇由 EMs 噁變而來的卵巢癌病例共43例（研究組），另選擇該組病例具有相同組織學亞型的卵巢癌病例共86例為對照組。比較兩組的臨床特徵併隨訪。結果研究組年齡﹤40歲患者的比率顯著高于對照組，術前 CA125水平正常的患者比率顯著高于對照組，化療週期≥6週期的患者比率顯著高于（ P ﹤0.05）。研究組患者中 FIGO 分期 I 期者比率較高，對照組則 III 期的比率高。研究組3年生存率為83.33%（35/42）高于對照組69.41%（59/85），但差異無統計學意義（χ2=2.984，P =0.015）。將兩組閤併後對影響生存率的因素進行 COX 迴歸分析髮現，FIGO 分期、是否 EMs 噁變、化療週期是影響卵巢癌患者生存的因素。結論 EMs 噁變是影響卵巢癌患者預後的重要危險因素，EMs 噁變而來的卵巢癌相對預後略好，但仍應爭取早期治療。
목적：비교분석란소자궁내막이위증（EMs）악변여란소암적림상특정급예후。방법선택유 EMs 악변이래적란소암병례공43례（연구조），령선택해조병례구유상동조직학아형적란소암병례공86례위대조조。비교량조적림상특정병수방。결과연구조년령﹤40세환자적비솔현저고우대조조，술전 CA125수평정상적환자비솔현저고우대조조，화료주기≥6주기적환자비솔현저고우（ P ﹤0.05）。연구조환자중 FIGO 분기 I 기자비솔교고，대조조칙 III 기적비솔고。연구조3년생존솔위83.33%（35/42）고우대조조69.41%（59/85），단차이무통계학의의（χ2=2.984，P =0.015）。장량조합병후대영향생존솔적인소진행 COX 회귀분석발현，FIGO 분기、시부 EMs 악변、화료주기시영향란소암환자생존적인소。결론 EMs 악변시영향란소암환자예후적중요위험인소，EMs 악변이래적란소암상대예후략호，단잉응쟁취조기치료。
Objective To investigate the clinical features and prognosis of malignant ovarian endometriosis and ovarian cancer. Methods A total of 43 cases of malignant ovarian cancer from EMs were collected for study group and the other patients with ovarian cancer were selected at same histological subtype as the control group. Clinical characteristics were compared and follow - up. Results In the study group,proportion of age ﹤ 40 years were significantly higher,preoperative normal CA125 levels was significantly higher,proportion of FIGO stage I was higher in the study group. In the control group,proportion of stage III patients was high. In the study group,patients with proportion of chemotherapy cycles ≥6 was significantly higher. 3 - year survival rate in study group was 83. 33%(35 / 42),which was higher than the control with 69. 41%(59 /85),but the difference was not statistically significant(log - rank χ2 = 2. 984,P = 0. 015). After the merger of the two groups,factors that in-fluence survival were taken by COX regression analysis:FIGO stage,whether EMs malignant,chemotherapy cycle factors affected the survival rate. Conclusion EMs malignant is an important risk factor that affecting the prognosis,which is slightly better than the prognosis of ovarian cancer,but still need early treatment.
